openPR Logo
Press release

Global Respiratory Drugs Market Forecast to Increase to $41.3 billion in 2023

Global Respiratory Drugs Market Forecast to Increase to $41.3

“The Report Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz”

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as inflammation, the scarring of lung tissue and excessive production of mucus in the airways. This report focuses on the key therapy area indications of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the underlying cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. However, over the past decade the treatment of respiratory disorders has developed significantly, with novel and targeted therapies emerging onto the market. The approval of the products Kalydeco and Orkambi, in 2012 and 2014 respectively, gave patients disease-modifying treatment options for CF. Targeted biologics have also emerged such as omalizumab and Nucala for the treatment of asthma.

Get Sample Copy Of This Report @
https://www.marketresearchreports.biz/sample/sample/1339595

Overall, 937 products are being actively developed in the respiratory pipeline. The pipelines of asthma, COPD, IPF and CF contain 261, 106, 79 and 131 products, respectively. Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area.

Scope

Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?

View Report @ https://www.marketresearchreports.biz/reports/1339595/global-respiratory-drugs-to-market-research-reports

Reasons to buy

Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 12
2.1 Therapy Area Introduction 12
2.2 Symptoms 13
2.3 Diagnosis 13
2.3.1 Asthma 13
2.3.2 Chronic Obstructive Pulmonary Disease 14
2.3.3 Idiopathic Pulmonary Fibrosis 15
2.3.4 Cystic Fibrosis 16
2.4 Etiology and Pathophysiology 16
2.4.1 Asthma 16
2.4.2 Chronic Obstructive Pulmonary Disease 18
2.4.3 Idiopathic Pulmonary Fibrosis 20
2.4.4 Cystic Fibrosis 22
2.5 Epidemiology 23
2.5.1 Asthma 24
2.5.2 Chronic Obstructive Pulmonary Disease 25
2.5.3 Idiopathic Pulmonary Fibrosis 26
2.5.4 Cystic Fibrosis 27
2.6 Prognosis and Disease Staging 28
2.6.1 Asthma 28
2.6.2 Chronic Obstructive Pulmonary Disease 31
2.6.3 Idiopathic Pulmonary Fibrosis 32
2.6.4 Cystic Fibrosis 34
2.7 Treatment 36
2.7.1 Asthma 36
2.7.2 Chronic Obstructive Pulmonary Disease 37
2.7.3 Idiopathic Pulmonary Fibrosis 38
2.7.4 Cystic Fibrosis 38

3 Key Marketed Products 41
3.1 Overview 41
3.2 Advair - GSK 42
3.3 Symbicort - AstraZeneca/Astellas 44
3.4 Spiriva - Boehringer Ingelheim 47
3.5 Xolair - Roche/Novartis 48
3.6 Ventolin - GSK 50
3.7 Pulmicort - Astra Zeneca 51
3.8 Orkambi - Vertex 52
3.9 Relvar/Breo Ellipta - GSK 54
3.10 Singulair - Merck & Co. 55
3.11 Esbriet - Roche 57
3.12 Kalydeco - Vertex 59
3.13 Conclusion 60

4 Pipeline Landscape Assessment 62
4.1 Overview 62
4.2 Pipeline Development Landscape 63
4.3 Molecular Targets in the Pipeline 66
4.4 Clinical Trials 68
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 68
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 72
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 76
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 80
4.5 Assessment of Key Pipeline Products 83
4.5.1 Ivacaftor and Tezacaftor - Vertex 83
4.5.2 (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva 84

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Respiratory Drugs Market Forecast to Increase to $41.3 billion in 2023 here

News-ID: 764328 • Views:

More Releases from MarketResearchReports.biz

Global Automotive Augmented Reality and Virtual Reality Market Breakdown Data by Regions, Type, Manufacturers and Applications, Forecast 2018-2025
Global Automotive Augmented Reality and Virtual Reality Market Breakdown Data by …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Augmented Reality and Virtual Reality Market Insights, Forecast to 2025” Augmented reality (AR) is a technology that adds on or layers digital media, such as touch feedback, graphics, 3D models, and sound, on a real world environment to enhance user experience and interaction. Virtual reality (VR) is a computer simulated reality that is achieved through replicating an environment
Global Artificial Intelligence in Transportation Market Breakdown Data by Regions, Type, Manufacturers and Applications
Global Artificial Intelligence in Transportation Market Breakdown Data by Region …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Artificial Intelligence in Transportation Market Insights, Forecast to 2025” Global Artificial Intelligence in Transportation market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size for Artificial
Global Automotive Wind Tunnel Testing Equipment Market Forecast to 2025: By Product, Application, Manufacturer, Sales and Segmentation
Global Automotive Wind Tunnel Testing Equipment Market Forecast to 2025: By Prod …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Wind Tunnel Testing Equipment Market Insights, Forecast to 2025” Global Automotive Wind Tunnel Testing Equipment market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size
Global Automotive Beauty Industry Analysis and Forecast 2018-2025
Global Automotive Beauty Industry Analysis and Forecast 2018-2025
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Beauty Market Insights, Forecast to 2025” This industry study presents the global Automotive Beauty market size, historical breakdown data (2013-2018) and forecast (2018-2025). The Automotive Beauty production, revenue and market share by manufacturers, key regions and type; The consumption of Automotive Beauty in volume terms are also provided for major countries (or regions), and for each application and product

All 5 Releases


More Releases for Fibrosis

Liver Fibrosis Pipeline: 50+ Companies Advancing Antifibrotic Therapies and Dise …
The therapeutic landscape for liver fibrosis, a pathological scarring process resulting from chronic liver injury, is rapidly evolving, as biopharmaceutical innovators shift their focus from symptomatic control to targeting the fibrogenic mechanisms driving disease progression. With no FDA-approved treatments specifically for reversing liver fibrosis, the spotlight is now on antifibrotic agents, inflammation modulators, and regenerative therapies aimed at halting or reversing fibrotic damage before it advances to liver fibrosis. Companies
Kidney Fibrosis Treatment Market - Revitalize Your Kidneys: Innovative Therapies …
Newark, New Castle, USA: The "Kidney Fibrosis Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Kidney Fibrosis Treatment Market: https://www.growthplusreports.com/report/kidney-fibrosis-treatment-market/8877 This latest report researches the industry structure,
Kidney Fibrosis Treatment Market - Leading the Way in Renal Fibrosis Management: …
Newark, New Castle, USA - new report, titled Kidney Fibrosis Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Kidney Fibrosis Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Kidney Fibrosis Treatment market. The report offers an overview of
Cystic Fibrosis Market Report-Growth with Industry Study, Detailed Analysis | Cy …
The research study contains an in detail descriptive overview and analysis of the Cystic Fibrosis Market, a summary of the market shares constituted by each component, the annual growth of each sector, and the revenue potential of the section. In addition, Cystic Fibrosis Market production and consumption data are used to determine the geographical features. Get FREE PDF sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3639856 Top Company Profile Analysis in this Report- Cystic Fibrosis
The Cystic Fibrosis Market to Witness Robust Growth Due to Increasing Cases of C …
Cystic fibrosis is a rare, progressive, life-threatening disease results in the formation of thick mucus that builds up in the lungs, digestive tract, and other parts of the body. If left untreated, it leads to severe digestive and respiratory problems as well as other complications such as infections and diabetes. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with cystic fibrosis around the world. As the
Fibrosis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fibrosis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis – Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape. Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the